<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195191</url>
  </required_header>
  <id_info>
    <org_study_id>2018713122010</org_study_id>
    <nct_id>NCT04195191</nct_id>
  </id_info>
  <brief_title>Intervention to Improve the Adherence in Community Pharmacies</brief_title>
  <official_title>Effectiveness of an Intervention to Improve the Adherence to Treatment of New Medicines From the Community Pharmacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ANM is the first initiative that puts advanced pharmaceutical care into practice in
      Andalusia (Spain). The aim of this is study is to evaluate the effectiveness of the
      intervention Assistance to New Medicines (ANM) in the improvement of adherence to treatment
      in community pharmacies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: parallel cluster pragmatic randomized controlled trial. The study includes patients
      users of a community pharmacies, who meet the following inclusion criteria: patient who
      starts treatment of any of the following pathologies: Chronic Obstructive Pulmonary Disease
      (COPD), Arterial Hypertension or Diabetes Mellitus in Andalusia (Spain).

      In order to avoid possible contamination between patients assigned to the control and
      intervention group, randomization will be carried out at the pharmacy level; preventing the
      pharmacist from applying part of the intervention to the control group.

      Interventions: patients randomized: (i) current practice; or (ii) ANM intervention thru a
      pharmacist delivered support for a newly prescribed medicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>cluster randomized controlled trial.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The statistical analysis will be performed by a person who would be blinded to which arm were assigned the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>Ten weeks</time_frame>
    <description>adherence to treatment may be defined as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>Six months</time_frame>
    <description>adherence to treatment may be defined as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the service</measure>
    <time_frame>Ten weeks and six months</time_frame>
    <description>The degree to which the individual regards the health care service or product or the manner in which it is delivered by the provider as useful, effective, or beneficial. The satisfaction with the service, will be collected thru a likert question (1 not satisfied, 10 very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD</condition>
  <condition>Arterial Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The usual practice by community pharmacies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ANM</intervention_name>
    <description>communication intervention</description>
    <arm_group_label>ANM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>regular assistance in community pharmacies</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patient who starts treatment of any of the following diseases:

          -  Chronic Obstructive Pulmonary Disease (COPD).

          -  Arterial Hypertension

          -  Diabetes Mellitus.

          -  Anticoagulants

        Exclusion Criteria:

          -  those users who do not know how to read and write in Spanish,

          -  Suffer from a physical or mental disorder that makes it impossible to perform the
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Olry de Labry Lima, PhD</last_name>
    <phone>958027400</phone>
    <email>antonio.olrylabry.easp@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia gomez</last_name>
    <phone>+34958027400</phone>
    <email>julia.gomez.easp@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andalusian School of Public Health &amp; CIBER en Epidemiología y Salud Pública (CIBERESP).</name>
      <address>
        <city>Granada</city>
        <zip>18080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Olry de Labry Lima, PhD</last_name>
      <phone>958027400</phone>
      <email>clara.bermudez.easp@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

